Pharmacogenetics and Genomics

Papers
(The median citation count of Pharmacogenetics and Genomics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-1966
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study24
PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics23
Identification of populations likely to benefit from pharmacogenomic testing15
Knowledge, attitude, and practice towards pharmacogenomics among hospital pharmacists in Thailand15
Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms14
Association between polymorphisms in the vitamin D receptor and susceptibility to multiple sclerosis13
Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles11
Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry10
A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators10
Cis-acting regulatory elements regulating CYP3A4 transcription in human liver9
Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism9
Patient insights on features of an effective pharmacogenomics patient portal9
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives8
Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients8
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine8
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria8
HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia8
Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia7
Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia7
Identification of high-impact gene–drug pairs for pharmacogenetic testing in Alberta, Canada7
N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes7
Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients7
Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance6
Impacts of interactions between ADH1B and ALDH2 genotypes on alcohol flushing, alcohol reeking on the day after drinking, and age distribution in Japanese alcohol-dependent men6
JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity5
Incorporating G6PD genotyping to identify patients with G6PD deficiency5
C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer5
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation5
Histone acetylation at the sulfotransferase 1a1 gene is associated with its hepatic expression in normal aging5
The effect of SLC6A3 variable number of tandem repeats and methylation levels on individual susceptibility to start tobacco smoking and on the ability of smokers to quit smoking5
Implementation of pharmacogenomics into inpatient general medicine4
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity4
Analytical validation of a laboratory-development multigene pharmacogenetic assay4
Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinica4
Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients4
Pharmacogenomics of thiopurines: distribution of TPMT and NUDT15 polymorphisms in the Brazilian Amazon4
Single Nucleotide Polymorphisms (SNPs) in PRKG1 & SPATA13-AS1 are associated with bronchodilator response: a pilot study during acute asthma exacerbations in African American children4
HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain4
Distribution and linkage disequilibrium of the enhancer SNP rs5758550 among Latin American populations: influence of continental ancestry3
Genome-wide DNA methylation profile of peripheral blood lymphocytes from subjects with nonsteroidal anti-inflammatory drug-induced respiratory diseases3
Identification of potential druggable targets of cell cycle with small-molecule inhibitors in oral squamous cell carcinoma3
Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis3
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis3
Methods and implementation of a pediatric asthma pharmacogenomic study in the emergency department setting3
Pharmacogenetics: a perspective and preparedness of Pharm-D and medical students in Jordan3
A novel NUDT15 variant identified in Caucasian TPMT wild type patients with inflammatory bowel disease and azathioprine-related myelotoxicity3
Pharmacogenetic analysis of canonical versus noncanonical pathway of NF-kB in Crohn’s disease patients under anti-tumor necrosis factor-α treatment2
MiRNA-139-3p inhibits malignant progression in urothelial carcinoma of the bladder via targeting KIF18B and inactivating Wnt/beta-catenin pathway2
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design2
Genetic association of primary nonresponse to anti-TNFα therapy in patients with inflammatory bowel disease2
Background sensitivity to chemotherapy-induced nausea and vomiting and response to antiemetics in paediatric patients: a genetic association study2
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)2
Contribution of APOA5, APOC3, CETP, ABCA1 and SIK3 genetic variants to hypertriglyceridemia development in Mexican HIV-patients receiving antiretroviral therapy2
In-vitro characterization of coding variants with predicted functional implications in the efflux transporter multidrug resistance protein 4 (MRP4, ABCC4)2
Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy2
Comparison of clinical pharmacogenetic recommendations across therapeutic areas2
PharmGKB summary: acyclovir/ganciclovir pathway2
Investigation of pharmacologic interactions between omeprazole and tacrolimus in a membranous nephropathy patient with CYP3A5 nonexpresser: a case report2
Abacavir adverse reactions related with HLA-B*57:01 haplotype in a large cohort of patients infected with HIV2
Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis2
Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer2
Ligand-specific pharmacogenetic effects of nonsynonymous mutations2
The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia2
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia2
NAT2 polymorphisms as a cause of metamizole-induced agranulocytosis2
0.015880107879639